osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

Nathan Bucay(Amgen (United States)), Ildiko Sarosi(Amgen (United States)), Colin R. Dunstan(Amgen (United States)), Sean Morony(Amgen (United States)), J E Tarpley(Amgen (United States)), C. Capparelli(Amgen (United States)), Sheila Scully(Amgen (United States)), Hong‐Lin Tan(Amgen (United States)), Weili Xu(Amgen (United States)), David L. Lacey(Amgen (United States)), W. J. Boyle(Amgen (United States)), W. Scott Simonet(Amgen (United States))
Genes & Development
May 1, 1998
Cited by 2,475Open Access
Full Text

Abstract

Osteoprotegerin (OPG) is a secreted protein that inhibits osteoclast formation. In this study the physiological role of OPG is investigated by generating OPG-deficient mice. Adolescent and adult OPG-/- mice exhibit a decrease in total bone density characterized by severe trabecular and cortical bone porosity, marked thinning of the parietal bones of the skull, and a high incidence of fractures. These findings demonstrate that OPG is a critical regulator of postnatal bone mass. Unexpectedly, OPG-deficient mice also exhibit medial calcification of the aorta and renal arteries, suggesting that regulation of OPG, its signaling pathway, or its ligand(s) may play a role in the long observed association between osteoporosis and vascular calcification.


Related Papers